Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 18/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL28796568 | 0.76 | AKT1 (0.54) | AKT1PIK3CBPIK3CDPIK3CACYP3A4 | |
| SCHEMBL28796489 | 0.74 | MEN1 (0.56) | AKT1PIK3CBPIK3CDPIK3CACYP3A4 | |
| SCHEMBL1031205 | 0.73 | AKT1 (0.72) | AKT1PIK3CBPIK3CDPIK3CACYP3A4 | |
| SCHEMBL27863831 | 0.72 | MEN1 (0.56) | AKT1PIK3CBPIK3CDPIK3CACYP3A4 | |
| SCHEMBL27508637 | 0.71 | MAPT (0.44) | AKT1PIK3CB | |
| SCHEMBL12476025 | 0.71 | AKT1 (1.00) | AKT1PIK3CBPIK3CDPIK3CACYP3A4 | |
| SCHEMBL27700148 | 0.69 | L3MBTL1 (0.46) | AKT1PIK3CB | |
| SCHEMBL28514506 | 0.68 | AKT1 (0.60) | AKT1PIK3CBPIK3CDPIK3CACYP3A4 | |
| SCHEMBL28517851 | 0.67 | RAF1 (0.51) | AKT1PIK3CBPIK3CDPIK3CACYP3A4 | |
| SCHEMBL16742890 | 0.66 | MAPT (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102548970-A | Novel (6-oxo-1, 6-dihydropyrimidin-2-yl) amide derivatives, process for their preparation and their medical use as akt (pkb) phosphorylation inhibitors | SANOFI AVENTIS | 2012-07-04 | — | — | CN | disclosed |